Shangyao Bokang Biopharmaceutical

Shangyao Bokang Biopharmaceutical is a specialized research and development subsidiary of Shanghai Pharmaceuticals (SPH) focused on the discovery and clinical development of innovative biological drugs and high-quality biosimilars. Based in Shanghai, the company serves as a key engine for SPH's biologics pipeline, particularly in the fields of oncology and immunology. Its portfolio includes several monoclonal antibodies, with its lead program targeting CD20 for the treatment of B-cell lymphomas currently in late-stage clinical trials. The company operates within the SPH Biopharmaceutical division, leveraging integrated resources for R&D, pilot production, and clinical management. Shangyao Bokang is instrumental in SPH's strategic transition toward becoming a global innovation-led biopharmaceutical player.